MedTrace Logo

Nabilone & Marijuana Addiction

NCT01025700 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2011-02-17

No results posted yet for this study

Summary

Safety of Nabilone in reducing marijuana craving

Conditions

  • Marijuana Smoking

Interventions

DRUG

Cesemat

1 mg capsule per day for 21 days

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Shaohua Lu, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-06-30
Completion
2010-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025700 on ClinicalTrials.gov